Icecure MedicalICCM +2.78%46 PS Ratio is 3.43 as of Jul. 02, 2026, which is 78% below its 10-year median of 15.76. GuruFocus rates ICCM with a GF Score™ of 46/100 and a GF Value™ of $21.32 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 805 Medical Devices & Instruments companies, Icecure Medical ranks worse than 54.91% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Icecure Medical's share price is $5.36.
Icecure Medical's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $1.56. Hence, Icecure Medical's PS Ratio for today is 3.43.
The historical rank and industry rank for Icecure Medical's PS Ratio or its related term are showing as below:
ICCM'
s PS Ratio Range Over the Past 10 Years
Min: 1.53 Med: 15.76 Max: 184.97
Current: 3.43
During the past 13 years, Icecure Medical's highest PS Ratio was 184.97. The lowest was 1.53. And the median was 15.76.
ICCM's PS Ratio is ranked worse than 54.91% of 805
companies
in the Medical Devices & Instruments industry
Industry Median: 2.93
vs ICCM: 3.43
Icecure Medical Ltd revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Icecure Medical was -15.60% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -13.40% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -24.10% per year.
During the past 10 years, the average Revenue per Share Growth Rate was -8.90% per year.
During the past 13 years, Icecure Medical's highest 3-Year average Revenue per Share Growth Rate was 27.10% per year. The lowest was -48.60% per year. And the median was -18.25% per year.
Back to Basics: PS Ratio
Icecure Medical (NAS:ICCM) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Icecure Medical PS Ratio Related Terms
Icecure Medical PS Ratio Historical Data
* Premium members only.
The historical data trend for Icecure Medical's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Icecure Medical's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Icecure Medical PS Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Icecure Medical's PS Ratio distribution charts can be found below:
* The bar in red indicates where Icecure Medical's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Icecure Medical's Share Price of today is $5.36. Icecure Medical's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.56.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Icecure Medical (ICCM) has a PS Ratio of 3.43 as of Jul. 02, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Icecure Medical and its competitors. This is 78% below median its historical median of 15.76. Over the past decade, Icecure Medical's PS Ratio has ranged from 1.53 to 184.97. According to the industry distribution chart, Icecure Medical ranks #442 out of 805 companies in the Medical Devices & Instruments industry, placing it in the top 54.9%.
Is Icecure Medical's PS Ratio too high?
Icecure Medical's current PS Ratio of 3.43 is 78% below median its 10-year median of 15.76. Over the past 10 years, this metric has ranged from a low of 1.53 to a high of 184.97. The Medical Devices & Instruments industry median PS Ratio is 2.93. Icecure Medical's value of 3.43 is 17.1% above this industry median. Based on the distribution chart, Icecure Medical ranks #442 out of 805 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Icecure Medical has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Icecure Medical's PS Ratio compare to LFWD and IRIX?
According to the Medical Devices & Instruments industry distribution chart, Icecure Medical ranks #442 out of 805 companies for PS Ratio. This places Icecure Medical in the lower half of its industry. The industry median PS Ratio is 2.93. Icecure Medical's value of 3.43 is 17.1% above this benchmark. Historically, Icecure Medical's own PS Ratio has ranged from 1.53 to 184.97 over the past decade. While the company's 10-year median is 15.76 vs. the industry median of 2.93, Icecure Medical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Devices & Instruments company?
The median PS Ratio among Medical Devices & Instruments companies is 2.93, based on 805 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Icecure Medical's current PS Ratio of 3.43 is 17.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Icecure Medical and its competitors. For the Medical Devices & Instruments industry, the median PS Ratio is 2.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Icecure Medical's current PS Ratio is 3.43, which is 78% below median its own 10-year median of 15.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Icecure Medical stock overvalued right now?
Based on GuruFocus' analysis, Icecure Medical (ICCM) is currently considered Possible Value Trap. The stock's GF Value™ is $21.32, compared to a current price of $5.36 — trading 74.9% below its estimated fair value. The current PS Ratio is 3.43, which is 78% below median its 10-year median of 15.76 and 17.1% above the Medical Devices & Instruments industry median of 2.93. Icecure Medical's overall GF Score™ is 46/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Icecure Medical (ICCM), the current PS Ratio is 3.43 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Icecure Medical (ICCM) Overvalued in 2026?
Based on GuruFocus' analysis, Icecure Medical stock appears to be undervalued.
The current stock price of $5.36 is trading 74.9% below its estimated GF Value™ of $21.32.
GuruFocus considers Icecure Medical to be Possible Value Trap.
Key valuation signals for ICCM:
PS Ratio: 3.43 (78% below median its 10-year median of 15.76)
GF Value™: $21.32 vs. price of $5.36 (74.9% below fair value)
Industry Position: 17.1% above the Medical Devices & Instruments median (#442 of 805)
No single metric tells the full story. See the ICCM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
46GF Score
Get the complete analysis for ICCM
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ICCM has been successfully added to your 
